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Background: The aim of this study was assessment of predictive factors of diabetic retinopathy.
Methods: A cross-sectional study was designed by recruiting 1228 type 2 diabetic patients from a diabetes referral
clinic over a six-month period (from July to December, 2012). Diabetes risk factors, complications, laboratory results
have been recorded.
Results: Of the 1228 diabetic patients (54% women, mean age 58.48 ± 9.94 years), prevalence of diabetes retinopathy was
26.6%. There were significant associations between retinopathy and family history of diabetes (p = 0.04), hypertension
(p = 0.0001), diabetic duration (p = 0.0001), poor glycemic control (p = 0.0001) and age of onset of diabetes (p = 0.0001).
However, no significant associations were found between retinopathy with dyslipidemia and obesity. In logistic
regression model, poor glycemic control (p = 0.014), hypertension (p = 0.0001), duration of diabetes (p = 0.0001) and
family history of diabetes (p = 0.012) independently predicted retinopathy after adjustment for age and sex.
Conclusions: Diabetic complications are resulting from an interaction from genes and environmental factors. A family
history of diabetes is pointing toward a possible genetic and epigenetic basis for diabetic retinopathy. Our findings
suggest the role of epigenetic modifications and metabolic memory in diabetic retinopathy in subjects with family
history of diabetes.
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Global epidemic of diabetes is a serious and a major
health care concern that results in reduced life expect-
ancy and increased morbidity due to disease-specific
micro- and macro vascular complications. The strongest
risk factors for diabetic micro vascular complications are
poor glycemic control and diabetes duration. It is noti-
fied, despite good glycemic control, vascular complica-
tions remain in most diabetic patients [1,2]. In addition,
diabetic complications may develop before diagnosis
[3,4].
Although it is accepted that diabetic complications re-
sult from abnormal metabolic environment engendered
by chronic hyperglycaemia, the risk of developing these* Correspondence: emrc@tums.ac.ir
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article, unless otherwise stated.complications is under the control of genetic factors. But
efforts to identify genetic variants have produced disap-
pointing. A family history of type 2 diabetes has been
suggested as a strong link to genetic factors. Genetic
susceptibility to diabetes and its complications was sup-
ported by some linkage and familial aggregation studies.
This evidence suggests that genetic contributions may
influence the development of vascular complications
[5-7]. Genome wide association studies demonstrated
some genetic variations could explain inter-individual
variations in the susceptibility to diabetic complications
[8-10]. However, in the absent of specific genes or loci
that show strong relationship with diabetic vascular
complications, several of clinical and epidemiological
studies have demonstrated that environmental factors as
well as genetic factors play an etiological role for onset
of diabetic vascular complications [11,12]. Familial clus-
tering of diabetic complications could result from sharedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 The baseline characteristics of the type 2 diabetic
patients
Characteristic Type 2 diabetic patients
(N = 1228) (mean ± SD)
Age- (year) 58.48 ± 9.94
duration of diabetes- (year) 11.33 ± 7.98
Age of onset- (year) 47.34 ± 11.05
Glycated haemoglobin-% 7.5 ± 1.68
Total cholesterol— mg/dl 149.41 ± 32.7
LDL - mg/dl 86.15 ± 30.64
HDL- mg/dl 44.39 ± 12.14
Triglycerides— mg/dl 154.56 ± 91.87
Systolic Blood pressure-mm Hg 126.5 ± 20.41
diastolic Blood pressure- mm Hg 74.6 ± 11.32
BMI (Kg/m2) 28.75 ± 5.63
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However, the exact nature of these two main etiological
factors and their pathogenic mechanisms are poorly
understood. Increasing knowledge about predictive fac-
tors of diabetic complications causes that they will be
preventable in diabetic patients. Early identification of
risk factors can help reduce the development and pro-
gression of diabetic micro vascular complications, and
improve patients' quality of life.
Individual SNPs may confer risk of vascular complica-
tions [13,14] but they are not useful as a predictive
factor for onset of complications and not clinically in-
formative [15]. Therefore, this study has been intended
assess predictive factors of diabetic micro vascular com-
plications that is caused by a combination of genetic and
environmental factors. For this aim, we have chosen
retinopathy that is the most common diabetic micro vas-
cular complication. This cross-sectional study was de-
signed to investigate prevalence of diabetic retinopathy
(DR), risk factors, laboratory results, glycemic control
and family history of diabetes in order to determine the
role of each factor to predict DR.
Methods
Setting
A cross-sectional study was performed on 1228 adults
with type 2 diabetes mellitus recruited from the diabetes
referral clinic of the Tehran University of Medical Sci-
ences over a six-month period (from July to December,
2012). The protocol for the research project has been
approved by Ethics Committee of Endocrinology and
Metabolism Research Institute of Tehran University of
medical sciences. Patients affected by Type 1 diabetes
were excluded from the study. The diagnosis of diabetes
type 2 was carried out and/or confirmed following the
American Diabetes Association criteria [16]; a fasting
blood glucose of greater than or equal to 126 mg/dL on
two separate occasions; a random (non-fasting) blood
glucose of greater than or equal to 200 mg/dL on two
separate occasions; or a blood glucose of greater than
200 mg/dL at 2 hours during a 75 gr oral glucose toler-
ance test.
Demographic character and clinical information in-
cluding sex, age, age at diabetes diagnostic, diabetes dur-
ation, current use of anti-diabetic, antihypertension, and
lipid-lowering medications, systolic and diastolic blood
pressure, cigarette smoking status, body mass index
(BMI), lipid profile, glycated haemoglobin (HbA1c), and
present of diabetes complications (retinopathy, nephrop-
athy, and coronary artery disease) were evaluated. Dia-
betic nephropathy was defined as persistent increased
urinary albumin excretion (UAE) ≥300 mg/24 h or total
proteinuria > 500 mg/24 h in the absence of other renal
diseases. Coronary artery disease was defined as thepresence of a visible luminal narrowing of 50% or more
in at least 1 coronary artery detected by angiography.
Retinopathy screening and diagnosis
Based on ADA guideline, annual eye examinations were
performed for all diabetic patients, for retinopathic pa-
tients each 6 month (by dilating the pupils with eye drops
and then carefully examining the retina) by an ophthal-
mologist. Fluorescein angiography was performed at risk
patients.
Definition of diabetes major risk factors
Hypertension was defined in subjects with a BP > 140/
90 mmHg or taking BP medication. Based on ADA criteria
dyslipidemia was defined as triglycerides (TG) > 250 mg/dl
and/or high-density lipoprotein (HDL) < 35 mg/dl [17].
Glycemic control was categorized into poor and good gly-
cemic control based on HbA1c ≥ 7% or HbA1c < 7%, re-
spectively. Obesity was classified based on BMI ≥30 kg/m2.
Statistical analysis
All statistical analyses were carried out using SPSS, ver-
sion 16. A descriptive analysis of all available variables
was performed. Logistic regression model was used to
examine associations of potential risk factors with dia-
betic retinopathy. Numerical variables are reported as
the mean ± standard deviation and categorical variables
are presented as percentages. The level of statistical sig-
nificance was 5%.
Results
The baseline characteristics of the 1228 diabetic patients
(54% women) are presented in Table 1. The prevalence of
diabetes risk factors including dyslipidemia, hypertension,
and obesity was 90.7%, 72.6%, and 35.7%, respectively. Poor
Table 2 Comparison risk factors in patients with and without retinopathy
Risk factors Patients with retinopathy (n = 279) Patients without retinopathy (n = 771) Pvalue
Age 60.35 ± 8.91 57.4 ± 10.05 0.0001
Sex (male) 47.0% 43.8% 0.37
Age of onset of diabetes 44.33 ± 10.55 48.2 ± 10.89 0.0001
Duration of diabetes 16.07 ± 8.44 9.39 ± 6.87 0.0001
Poor glycemic control 69.7% (184/264) 52.8% (374/708) 0.0001
hypertension 85.2% (236/277) 69.2% (529/765) 0.0001
dyslipidemia 93.9% (262/279) 91.2% (701/769) 0.15
Obesity 36.8% (75/204) 34.4% (217/630) 0.54
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patients.
At least one diabetic complication (cardiovascular dis-
eases, retinopathy, and nephropathy) was diagnosed in
477 diabetic patients (52.6%). The prevalence of diabetes
nephropathy, cardiovascular diseases and diabetes retin-
opathy were 10.7%, 17.7%, and 26.6%, respectively.
The total of 1050 patients had ophthalmic data avail-
able for analyses. Among patients with retinopathy,
the prevalence of non-proliferative diabetes retinopathy
(NPDR), proliferative diabetes retinopathy (PDR), and
clinically significant macular edema (in patients with
and without PDR, NPDR) was 65.8%, 8.7% and 29.5%,
respectively. Patients with retinopathy were tended to be
older, with a longer duration of diabetes (p = 0.0001) and
earlier mean age of onset of diabetes (p = 0.0001),
(Table 2). Poor glycemic control was observed in 69.7%
patients with retinopathy compare to 52.8% in patients
without retinopathy (p = 0.0001). Among diabetic risk
factors, there were significant associations between ret-
inopathy and a family history of diabetes (OR = 1.59,Figure 1 Model proposing a role for retinopathy risk factors in relate95% CI: 1.003 to 2.28, p = 0.04), and hypertension (OR=1.60,
95% CI: 1.68 to 3.55, p = 0.0001). However, no signifi-
cant associations were found between retinopathy with
dyslipidemia (p = 0.41) and obesity (p = 0.54). The
prevalence of retinopathy in patients with first and sec-
ond degree family history of diabetes was significantly
higher than patients without family history of diabetes;
26.2% (167/638), 37.7% (29/77), and 19.9% (32/161), re-
spectively (p = 0.012).
In diabetic patients with family history of diabetes,
there was significant association between poor glycemic
control and DR (p = 0.001). In contrast, in diabetic pa-
tients without family history of diabetes, there was not
association between glycemic control and DR (p = 0.09).
Overall, diabetic patients with family history of dia-
betic had higher prevalence of hypertension (78.5% vs.
21.5%, 95% CI: 0.4 to 0.88, p = 0.009), and earlier age at
onset (49.78 ± 11.73 vs. 46.64 ± 10.83) (95% CI: 1.4 to
4.8, p = 0.0001) than those without family history.
To investigate predictive factors of DR, a logistic re-
gression model was used. In this model, after adjustingd to each other.
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hypertension (p = 0.0001, OR = 2.33), duration of dia-
betes (p = 0.0001, OR = 4.27) and family history of dia-
betes (p = 0.012, OR = 1.41) were independent predictors
of retinopathy. In this model, there were not significant
relationships between obesity (p = 0.54), and dyslipid-
emia (p = 0.10).Discussion
Diabetic retinopathy is most severe microvascular com-
plication in patients with Type 2 Diabetes which leading
cause of vision loss in working-aged adults (20–74 years)
[18]. High prevalence of DR in type 2 diabetic patients
imposes a large economic burden and public health con-
cern on the national healthcare system [18]. In our study
the prevalence of DR in patients with type 2 diabetes
was 26.6%. Our study has clarified that poor glycemic
control, duration of diabetes, hypertension and family
history of diabetes are the most important predictors of
DR. The underlying causes and prediction factors of DR
have not been completely elucidated. Severity of hyper-
glycemia, present of hypertension and diabetes duration;
are widely recognized as major risk factors for the devel-
opment of DR [19,20]; however explained approximately
10% of variation in DR [21-23].
Epidemiological studies have suggested primarily in-
tensive glycemic control can delay the development of
DR [19,20]. It is however noteworthy that some patients
may still develop DR even with good glycemic control.
Although our result has shown duration of diabetes to
be related to development of DR, it may begin to de-
velop as early as 7 years before the diagnosis of diabetes
in patients with type 2 diabetes [4]. Our finding has
showed that family history of diabetes is an independent
predictor of DR. In addition; a family history of diabetes
synergistically modifies association between poor gly-
cemic control and risk of DR development (Figure 1).
Our results confirmed with sibling, twin and family
studies. Heritability scores with ranging from 27-52% in
both type 1 and type 2 diabetes were reported in these
studies and also retinopathy aggregates in family studies
[7,24-26].
Although studies of familial aggregation suggested that
genetic factor influence on onset of DR or its severity,
genetic studies reported conflicting results [25,26]. Sev-
eral candidate genes and loci were associated with DR.
However, few of them have been replicated [27], with
weak genetic associations [13,14,28]. In addition, genetic
variations only were associated with a small proportion
of the total phenotypic variation, even for conditions
that are known to be highly heritable [29]. Therefore, a
family history of diabetes suggests familial genetic and
epigenetic contributions to the disease complications.Epigenetics is a newer area of research beginning to
make clear gene-environmental interactions and to iden-
tify factors that may alter gene expression and function
across the lifespan. Epigenetic processes may be particu-
larly important for understanding complex disorders like
diabetes because they are consistently heritable despite
having relatively weak and inconsistent association with
individual genetic variants. There is growing evidence
that gene-gene interactions and gene-environmental in-
teractions play an important role in determining an indi-
vidual’s risk of various common diseases including
diabetes [30]. Recent evidence shows that most gene
expressions and gene-environmental interactions are
mediated by epigenetic modulations [31-33]. Epigenetic
mechanisms provide a framework to incorporate envir-
onmental factors into models of complex disorder risks.
In particular, it has been noted that some individuals
with diabetes experience a continued progression of vas-
cular complications even after glycemic control subse-
quent to a period of prior hyperglycaemic exposure, a
phenomenon termed ‘metabolic memory'. “Metabolic
Memory”, is the idea that early glycemic environment is
remembered in the target organs [34] which has been
demonstrated in large multiple clinical trials [19,35].
These studies demonstrated that intensive glycemic con-
trol could reduce the progression of diabetic complica-
tions but could not prevent them. Compelling evidence
exists suggesting that exposure to an adverse fetal and/
or early postnatal environment may enhance susceptibil-
ity to a number of chronic diseases in the future life of
offspring. Furthermore, this evidence supports epigenetic
mechanisms as important components in metabolic mem-
ory and the pathology of diabetic complications [32]. But
this hypothesis remains to be confirmed.
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